Pharsight

Fosrenol generic

Fosrenol is a drug owned by Takeda Pharms Usa that was first authorized for market use on 24 September, 2014. It contains the active ingredient lanthanum carbonate, and is available in oral powder dosage forms.

When will Fosrenol generic be available?

The generics of Fosrenol are likely to be available after 01 December, 2030, which is the expiry date of its last patent. This means that after this date, other pharmaceutical manufacturers could potentially release a Fosrenol generic, assuming no litigation delays or additional patents are granted.

Fosrenol uses

Fosrenol, with its active ingredient lanthanum carbonate, is primarily utilized for the reduction of serum phosphate in patients with end stage renal disease.

Fosrenol patent expiration

Fosrenol holds a total of 4 patents, none of which have expired. The last patent for Fosrenol generic is set to expire on 01 December, 2030. Below are the details of the patent:

EPO Oppostions filed on Fosrenol

Fosrenol dosage

Want to ask something?